Question 1

What is the catalog number for K-777?

Accepted Answer

The catalog number for K-777 is M15857.

Question 2

What sizes are available for K-777?

Accepted Answer

K-777 is available in the following size(s): 1 g, 100 mg, 200 mg, 500 mg, Inquire.

Question 3

How many pack sizes does K-777 come in?

Accepted Answer

K-777 is available in 5 different pack sizes.

Question 4

Is K-777 in stock?

Accepted Answer

K-777 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is K-777 used for?

Accepted Answer

K-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively.

Question 6

What applications has this product been validated for?

Accepted Answer

Validated applications such as WB, ELISA, IHC, ICC, or FC are listed on the product datasheet. If you need application-specific validation data before ordering, contact our technical support team with the catalogue number.

Question 7

How do I reconstitute this lyophilized product?

Accepted Answer

Reconstitution instructions, including the recommended diluent and final concentration, are provided on the datasheet. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles.

Question 8

What is the recommended incubation time for this antibody?

Accepted Answer

A suggested incubation time is provided in the recommended protocol on the datasheet, but may need adjusting depending on your sample type and detection system.

K-777

Product Specifications

CAS Number

Stability

Purity

Weight

Molecular Formula

Notes

Receptor

Available Sizes

Frequently Asked Questions

Explore Other Products

Posdinemab (Biosimilar Reference Antibody) (MAPT)

Posdinemab (Biosimilar Reference Antibody) (MAPT)

Posdinemab (Biosimilar Reference Antibody) (MAPT)

Posdinemab (Biosimilar Reference Antibody) (MAPT)

Posdinemab (Biosimilar Reference Antibody) (MAPT)

Posdinemab (Biosimilar Reference Antibody) (MAPT)